Unknown

Dataset Information

0

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.


ABSTRACT: Neuroblastoma, a childhood cancer that originates from neural crest-derived cells, is the most common deadly solid tumor of infancy. Amplification of the MYCN oncogene, which occurs in approximately 20-25% of human neuroblastomas, is the most prominent genetic marker of high-stage disease. The availability of valid preclinical in vivo models is a prerequisite to develop novel targeted therapies. We here report on the generation of transgenic mice with Cre-conditional induction of MYCN in dopamine ?-hydroxylase-expressing cells, termed LSL-MYCN;Dbh-iCre. These mice develop neuroblastic tumors with an incidence of >75%, regardless of strain background. Molecular profiling of tumors revealed upregulation of the MYCN-dependent miR-17-92 cluster as well as expression of neuroblastoma marker genes, including tyrosine hydroxylase and the neural cell adhesion molecule 1. Gene set enrichment analyses demonstrated significant correlation with MYC-associated expression patterns. Array comparative genome hybridization showed that chromosomal aberrations in LSL-MYCN;Dbh-iCre tumors were syntenic to those observed in human neuroblastomas. Treatment of a cell line established from a tumor derived from a LSL-MYCN;Dbh-iCre mouse with JQ1 or MLN8237 reduced cell viability and demonstrated oncogene addiction to MYCN. Here we report establishment of the first Cre-conditional human MYCN-driven mouse model for neuroblastoma that closely recapitulates the human disease with respect to tumor localization, histology, marker expression and genomic make up. This mouse model is a valuable tool for further functional studies and to assess the effect of targeted therapies.

SUBMITTER: Althoff K 

PROVIDER: S-EPMC4487199 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


Neuroblastoma, a childhood cancer that originates from neural crest-derived cells, is the most common deadly solid tumor of infancy. Amplification of the MYCN oncogene, which occurs in approximately 20-25% of human neuroblastomas, is the most prominent genetic marker of high-stage disease. The availability of valid preclinical in vivo models is a prerequisite to develop novel targeted therapies. We here report on the generation of transgenic mice with Cre-conditional induction of MYCN in dopamin  ...[more]

Similar Datasets

| S-EPMC4467143 | biostudies-literature
| S-EPMC5539201 | biostudies-literature
| S-EPMC8178188 | biostudies-literature
| S-EPMC4837470 | biostudies-literature
2020-12-11 | PXD018300 | Pride
| S-EPMC9240069 | biostudies-literature
| S-EPMC5330763 | biostudies-literature
| S-EPMC3514490 | biostudies-literature
| S-EPMC5423163 | biostudies-literature
| S-EPMC9022217 | biostudies-literature